NCT01869634View on ClinicalTrials.gov

Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART

PHASE4CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

June 30, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Human Immunodeficiency Virus Infection
Interventions
DRUG

darunavir with ritonavir and fixed-dose viread+emtricitabine daily

Trial Locations (1)

95617

University of California Davis, Sacramento

All Listed Sponsors
lead

University of California, Davis

OTHER

NCT01869634 - Mechanisms of Immune Reconstitution & Reduced Immune Activation Following Darunavir-based ART | Biotech Hunter | Biotech Hunter